1. Home
  2. DXLG vs CTSO Comparison

DXLG vs CTSO Comparison

Compare DXLG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.50

Market Cap

38.2M

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.72

Market Cap

45.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
CTSO
Founded
1976
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2M
45.7M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
DXLG
CTSO
Price
$0.50
$0.72
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$2.50
$5.38
AVG Volume (30 Days)
110.8K
67.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$467,015,000.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
$3.24
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$0.47
$0.60
52 Week High
$2.07
$1.39

Technical Indicators

Market Signals
Indicator
DXLG
CTSO
Relative Strength Index (RSI) 38.04 46.87
Support Level N/A $0.62
Resistance Level $0.57 $0.74
Average True Range (ATR) 0.05 0.05
MACD 0.01 -0.00
Stochastic Oscillator 12.09 18.02

Price Performance

Historical Comparison
DXLG
CTSO

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: